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Difficult to control atopic dermatitis (AD) presents a therapeutic challenge and often requires combinations of
topical and systemic treatment. Anti-inflammatory treatment of severe AD most commonly includes topical
glucocorticosteroids and topical calcineurin antagonists used for exacerbation management and more recently for
proactive therapy in selected cases. Topical corticosteroids remain the mainstay of therapy, the topical calcineurin
inhibitors tacrolimus and pimecrolimus are preferred in certain locations. Systemic anti-inflammatory treatment is an
option for severe refractory cases. Microbial colonization and superinfection contribute to disease exacerbation and
thus justify additional antimicrobial / antiseptic treatment. Systemic antihistamines (H1) may relieve pruritus but do
not have sufficient effect on eczema. Adjuvant therapy includes UV irradiation preferably of UVA1 wavelength.
“Eczema school” educational programs have been proven to be helpful.
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Atopic dermatitis (AD, atopic eczema, eczema) is an
inflammatory, chronically relapsing, and intensely pruritic
skin disease occurring often in families with atopic diseases
(atopic dermatitis, bronchial asthma and/or allergic
rhino-conjunctivitis) [1]. Less than 10% are regarded
as severe cases because of disease intensity and extent
(SCORAD > 40) or refractory to treatment. Reasons for
severe courses of AD are based on individual (e.g. genetic,
barrier function, allergies) risc factors and sometimes on
therapeutic problems like misunderstandings with regard
to topical treatment. Management of exacerbated AD is a
therapeutic challenge, as it requires efficient short-term
control of acute symptoms, without compromising the
overall management plan that is aimed at long-term
stabilization, flare prevention, and avoidance of side effects.
Exacerbations may sometimes uncover relevant provoca-
tion factors, for example contact allergy, or infection. This
synopsis on refractory AD excludes the general principles
of AD treatment like basic skin care and management of* Correspondence: ulf.darsow@lrz.tum.de
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reproduction in any medium, provided the orfood allergy, as these main strategies are published else-
where in guidelines [2]. Nevertheless, these basic rules have
to be included in the management of all severe cases, too.
Figure 1 summarizes the general treatment options.Contact allergy
The role of contact allergy in AD patients is frequently
underestimated [3,4]. The frequency of contact sensitiza-
tion in AD, ranging from 41% to 64% according to
recent observations, supports the importance of systematic
patch testing in atopic patients, adults and children. The
most common contact sensitizers are metals, fragrance,
preservatives, dyes, neomycin, and lanolin, but contact
allergy to topical glucocorticosteroids is also not rare
in AD patients.
Contact sensitization may worsen the skin condition
of AD patients and influence the course of the disease.
Moreover, sensitized AD subjects may respond to very
low concentrations of contact allergens, because of their
impaired skin barrier function and hyper-reactivity to
irritant stimuli enhancing contact reactions.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
BASELINE
Basic Therapy
MILD: objective 
SCORAD <15 /
transient eczema
MODERATE: objective 
SCORAD 15-40 /
recurrent eczema
SEVERE: objective 
SCORAD >40 /
persistent eczema
• For every phase, additional therapeutic options are given
• Add antiseptics / antibiotics in cases of superinfection
• Allergen-specific immunotherapy in selected cases with relevant sensitization
• Consider compliance and diagnosis, if therapy has no effect
Hospitalization, systemic 
immunosuppression: oral 
glucocorticosteroids, cyclosporin 
A, PUVA, azathioprin, oral 
tacrolimus, mycophenolate mofetil
Sedating antihistamines 
(doxepin, hydroxyzine), UV 
therapy (UVB 311 nm, UVA1), 
psychosomatic counseling, 
climate therapy
Topical glucocorticosteroids or 
depending on local cofactors: topical 
calcineurin inhibitors, antiseptics incl. 
silver / AEGIS underwear, non-sedating 
antihistamines (controversial)
Educational programmes, emollients, 
bath oils, elimination diet in food-
allergic patients, allergen avoidance 
(encasings, if diagnosed by allergy 
tests)
Figure 1 Recommendation for treatment of adult eczema / atopic dermatitis according to graded severity (modified from 44).
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Topical treatment
The use of wet-wrap dressings with (diluted) corticosteroids
for up to 14 days (usually applied for 3 days) is a safe crisis
intervention treatment of severe and/or refractory AD with
temporary systemic bioactivity of the corticosteroids as the
only reported serious side-effects [5,6]. By tradition, anti-
inflammatory topical therapy has been administered to
lesional skin only and has been stopped or tapered down
once visible lesions were cleared. This traditional, reactive
approach has in the last years been challenged by the pro-
active treatment concept, which is defined as a combination
of pre-defined, long-term, low dose, anti-inflammatory
treatment applied to previously affected areas of skin in
combination with liberal use of emollients on the entire
body and a predefined appointment schedule for clinical
control examinations [7,8].Corticosteroids
Topical corticosteroids (TCS) are a first line anti-
inflammatory treatment, applied on inflammatory skin
lesions according to needs (pruritus, sleeplessness, new
flare). Proactive therapy for flare prevention is also
possible with TCS.Topical corticosteroids are grouped by
potency, which should be known to prescribers. Potent
and very potent corticosteroids (group III and IV) are
more likely to cause depression of adrenal function than
group I (mild) and II (moderate strength) treatments, but
their systemic effects will decrease more quickly due to
more rapid restitution of the skin barrier [9,10]. However,
potency ranking of topical steroids in some countries
including the US is the reverse of the European systemwith class I (superpotent) to class VII (low potency). For
severe AD, group II and group III (EU system) glucocor-
ticosteroids are recommended. Itch is the key symptom
for evaluation of response to treatment, and tapering
should not be initiated before the itch has disappeared.
Dose tapering should be gradual in order to avoid
withdrawal rebound. Tapering strategies consist in using a
less potent corticosteroid on a daily base, or keeping a more
potent one while reducing the frequency of application
(intermittent regimen).Topical calcineurin inhibitors
Both topical calcineurin inhibitors (TCI), tacrolimus
ointment (0.1% and 0.03%) and pimecrolimus cream
(1%), are licensed for topical eczema treatment. Various as-
pects of these drugs have been reviewed in detail [11]. The
efficacy of both formulations has been demonstrated
against placebo in clinical trials for short term [12,13] and
long term use of these substances [14,15]. In addition,
proactive tacrolimus ointment therapy has been shown to
be safe and effective for up to one year in reducing the
number of flares and improving the quality of life in adult
patients and children [16,17]. The anti-inflammatory
potency of 0.1% tacrolimus ointment is similar to a cortico-
steroid with intermediate activity [18], while the latter is
clearly more active than 1.0% pimecrolimus cream [19].Antihistamines
Systemic antihistamines (anti H1) are widely used in
acute flares against itch, however few controlled studies
are available [20]. Antihistamines may be helpful in
decreasing pruritus and permit sleep during flares. In
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are recommended by clinicians as helpful. Concerning the
newer non-sedating H1R specific antihistamines, controlled
studies did not show significant effects on eczema.
Anti-bacterial and antimycotic therapy
A number of defects in innate and adaptive immunity may
explain the high rate of cutaneous colonization with
Staphylococcus aureus (up to 90% in moderate to severe
eczema) in AD [21]. There is evidence that a decrease in
microbiome diversity is associated with an increased
colonization with S. aureus as well as increase in disease
activity. Antibiotic eradication of S. aureus may therefore
not always be an appropriate long-term strategy, especially
with regard to the increasing prevalence of antibiotic resist-
ance [22-24]. In particular topical antibiotics should not be
used for longer periods in the treatment of AD. There is
evidence for an association of S. aureus-derived superan-
tigens with disease exacerbation [25,26], supporting early
observations that the density of S. aureus colonization in
AD is significantly correlated with clinical severity [27], and
that patients with severe AD may improve (but not be
cured) by anti-staphylococcal treatment [28]. In general,
improvement of eczema by anti-inflammatory therapy
(i.e. TCS, TCI, UV) decreases S. aureus colonization.
Other secondary infections, such as yeasts, dermato-
phytes, and streptococcal infections have also been
implicated as disease factors in AD (for a review, see
[22]). Intense, fleshy erythema in skin folds of children
with a flare of AD may warrant a search for streptococ-
cal skin infection. In general, signs of secondary infec-
tions should be treated if present. Ketoconazole and
ciclopiroxolamine are proposed for topical treatment of
“head and neck” AD, often associated with Malassezia
sympodialis superinfection [29,30].
Phototherapy
Except UVA1, which was shown to be effective in
managing AD flares, phototherapy is not indicated in
the acute stages of AD, but apt to treat chronic, pruritic,
lichenified forms. However, it should not be prescribed in
patients who experienced a worsening of their dermatosis
during sun exposure. Usually, phototherapy is part of a total
treatment plan in addition to topical anti-inflammatory and
antimicrobial therapy. As second-level treatment it is
used especially in adults. Phototherapy in children youn-
ger than 12 years should not be applied under normal
circumstances.
Present UV sources include equipments able to emit
selective spectra of radiations
– Broadband UV (UVA+UVB = 290–400 nm)
– Narrow-band UVB (nbUVB = peak:311–313 nm)
– UVA1 (340–400 nm).nbUVB has been indicated for chronic-moderate forms
of AD [31] and is currently preferred to broadband UV
because it is less erythemogenic, while high dose UVA1
has been prescribed for more severe phases [31].
Systemic anti-inflammatory therapy
Non-response to adequately applied topical therapy is
rare, and systemic anti-inflammatory treatment should
be limited to severe cases in which the potential of
topical treatment (or of patient compliance) has been
exhausted. An actual overview of the different options
has been published [32]. Corticosteroids are rapidly
effective, but should only be used for a few weeks,
for severe acute exacerbations, because of the many
long term side-effects. In severe chronic cases consider
starting another systemic anti-inflammatory therapy while
tapering the corticosteroid.
The usefulness of both cyclosporin (3–5 mg/kg/day)
and azathioprine (2.5 mg/kg/day) has been well docu-
mented in clinical trials with children and adults [33-36].
Cyclosporin A therapy is rapidly effective, but has a narrow
therapeutic index and requires a close follow-up of renal
function. It is an approved substance for systemic treat-
ment of AD in many countries and is frequently used for
systemic immunosuppressive therapy in AD.
Azathioprine has a slower onset of action and is not
always well tolerated. Low TPMT (thiopurineme-
thyltransferase) activity is associated with an increased
myelotoxicity of azathioprine, but patients at risk can
be identified by pre-treatment screening for TMTP
activity [35].
Mycophenolate mofetil (2g/day) seems to offer a com-
paratively more favourable safety profile and its usefulness
in severe AD is documented in both prospective and
retrospective studies [37-39], but remains to be assessed
in larger randomized trials.
Methotrexate is used by many clinicians as an alterna-
tive treatment. Only a few studies have documented its
effect and more randomised trials are needed [40].
Biologic agents (biologicals) present new therapeutic
tools in the treatment of recalcitrant AD. They specifically
target inflammatory cells and mediators, respectively, and
thus may inhibit pathogenically relevant pathways. A
number of case reports and pilot studies have been
published recently, however representative, randomized,
placebo controlled studies evaluating the efficacy and
safety of biologicals in AD are still not available.
Approaches resulting in reduced T cell activation using
agents such as alefacept (fusion protein of lymphocyte
function antigen (LFA)-3 (CD58) and immunoglobulin
(Ig)G, rituximab (anti-CD20 antibody) and efalizumab
(anti-CD11a antibody, no longer available) have been
shown to be effective in selected patients with moderate
to severe AD and were mentioned in guidelines [2,41-44].
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In the last decade, education programs for patients
and parents were established in different countries in
Europe, but also in North and South America (see
www.opened-dermatology.com). Standardized interdis-
ciplinary programs involving dermatologists, paediatri-
cians, psychologists / psychosomatic counsellors, and
dietary counselling have been demonstrated to support
the improvement of subjective and objective symptoms,
and optimize medication use in patients, and result in a
significant gain in quality of life [45]. Participation in one
of these programs is highly encouraged.
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